Company profile for Engrail Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Acquiring, developing and commercializing transformative medicines. We are forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage ou...
Acquiring, developing and commercializing transformative medicines. We are forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
12750 High Bluff Drive, Suite 190, San Diego, CA 92130
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/09/18/2948077/0/en/Engrail-Therapeutics-Initiates-ENX-104-Clinical-Program-for-the-Treatment-of-Major-Depressive-Disorder-Characterized-by-Anhedonia.html

GLOBENEWSWIRE
18 Sep 2024

https://www.globenewswire.com/news-release/2024/08/08/2926765/0/en/Engrail-Therapeutics-Appoints-Paul-Cayer-as-Chief-Financial-Officer-and-Saira-Ramasastry-to-Board-of-Directors.html

GLOBENEWSWIRE
08 Aug 2024

https://www.biospace.com/article/engrail-raises-157m-in-oversubscribed-series-b-to-move-neuro-pipeline-forward-/

Tyler Patchen BIOSPACE
20 Mar 2024

https://www.businesswire.com/news/home/20240319356943/en

BUSINESSWIRE
19 Mar 2024

https://www.businesswire.com/news/home/20230718888096/en

BUSINESSWIRE
18 Jul 2023

https://www.businesswire.com/news/home/20220607005544/en

BUSINESSWIRE
07 Jun 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty